1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66.
2. di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer. 1992, 70: 254-68. 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E.
3. Bostwick DG, Foster CS, Algaba F, Hutter RVP, Montironi R, Mostofi FK, et al: Prostate tissue factors. Prostate cancer. Second international consultation on prostate cancer. Edited by: Murphy G, Denis L, Khoury S, Partin A, Denis L. 2000, Plymouth: Plymbridge Distributors, 162-201.
4. Ather MH, Shariff AH: Prognostic and Therapeutic Value Neuro Endocrine Differentiation as Manifested by Circulating Chromogranin A in Prostate Carcinoma. Prostate cancer. Edited by: John N Lucas. Nova science Publishers, New York, US
5. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S: Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage. BMC Urol. 2004, 4: 14-17. 10.1186/1471-2490-4-14.